(19)
(11) EP 1 185 712 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.10.2005 Bulletin 2005/42

(45) Mention of the grant of the patent:
17.08.2005 Bulletin 2005/33

(21) Application number: 00936827.5

(22) Date of filing: 25.05.2000
(51) International Patent Classification (IPC)7C12Q 1/70, C12Q 1/68, A61K 31/44, A61K 31/505, A61P 31/18, G06F 19/00
(86) International application number:
PCT/EP2000/004915
(87) International publication number:
WO 2000/073511 (07.12.2000 Gazette 2000/49)

(54)

NEW MUTATIONAL PROFILES IN HIV-1 REVERSE TRANSCRIPTASE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE

NEUE MUTATIONSPROFILE DER HIV-1 REVERSE TRANSCRIPTASE IN VERBINDUNG MIT PHÄNOTYPISCHEM MEDIKAMENTRESISTENZ

NOUVEAUX PROFILS MUTATIONNELS DANS LA TRANSCRIPTASE INVERSE DU VIH-1 EN RELATION AVEC UNE PHARMACORESISTANCE PHENOTYPIQUE


(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 28.05.1999 US 136743 P

(43) Date of publication of application:
13.03.2002 Bulletin 2002/11

(73) Proprietor: VIRCO BVBA
2800 Mechelen (BE)

(72) Inventors:
  • HERTOGS, Kurt
    B-2018 Antwerpen (BE)
  • LARDER, Brendan
    Cambridge CB37HQ (GB)
  • PAUWELS, Rudi, Wilfried, Jan
    B-2820 Bonheiden (BE)

(74) Representative: Daelemans, Frank F.R. 
Tibotec-Virco N.V., General De Wittelaan L11 B3
B-2800 Mechelen
B-2800 Mechelen (BE)


(56) References cited: : 
WO-A-97/27332
   
  • LARDER B ET AL: "A complete survey in over 1,500 clinical HIV-1 isolates of phenotypic and genotypic protease resistance profiles and their relation to therapy history" AIDS, vol. 12, no. suppl. 4, November 1998 (1998-11), page S11 XP000952507
  • HERTOGS K ET AL: "Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis" AIDS, vol. 12, no. suppl. 4, November 1998 (1998-11), page S11 XP000952505
  • LARDER B: "Reverse transcriptase inhibitors" AIDS, vol. 12, no. suppl. 4, 1998, page S3 XP000952508
  • LARDER B ET AL: "Closing in on drug resistance" NATURE STRUCTURAL BIOLOGY, vol. 6, no. 2, February 1999 (1999-02), pages 103-106, XP000946885
  • HERTOGS K ET AL: "A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 2, February 1998 (1998-02), pages 269-76, XP000946883
  • MILLER V ET AL: "Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with nonnucleoside transcriptase inhibitors " ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 12, December 1998 (1998-12), pages 3123-29, XP000952614
  • WINTERS M ET AL: "A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors" JOURNAL OF CLINICAL INVESTIGATION, vol. 102, November 1998 (1998-11), pages 1769-75, XP000952589
  • SCHINAZI R ET AL: "Mutations in retroviral genes associated with drug resistance" INTERNATIONAL VIRAL NEWS, vol. 5, no. 8, - 1997 pages 129-42, XP000861634
  • IVERSEN A ET AL: "Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy" JOURNAL OF VIROLOGY, vol. 70, no. 2, February 1996 (1996-02), pages 1086-90, XP002150115
  • CONDRA J ET AL: "Genetic correlation of in vivo viral isolates to indinavir, a human immunodeficiency type 1 protease inhibitor" JOURNAL OF VIROLOGY, vol. 70, no. 12, December 1996 (1996-12), pages 8270-76, XP002150116
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).